{"profile":{"id":"bc61391e-480a-4a3a-8ff3-f9603eeb7668","slug":"clexio-biosciences-ltd-petah-tikva-08e4","business_name":"Clexio Biosciences Ltd.","website_url":"https://www.clexio.com","industry":"Biotechnology company","city":"Petah Tikva","services":[{"category":"product","price_range":null,"service_area":null,"service_name":"CLE-100 NMDA Antagonist","target_customer":"Patients with Major Depressive Disorder","factual_description":"A lead drug candidate currently in Phase 2 multicenter studies for Major Depressive Disorder.","related_capabilities":[]},{"category":"product","price_range":null,"service_area":null,"service_name":"CLE-043 KV7.2/3 Channel Opener","target_customer":"Patients with neuropsychiatric conditions","factual_description":"A drug candidate in the preclinical stage, with a lead compound identified for potential neuropsychiatric applications.","related_capabilities":[]},{"category":"service","price_range":null,"service_area":null,"service_name":"Novel Drug Development","target_customer":"Patients with unmet needs in neuropsychiatric conditions","factual_description":"Designing innovative therapies based on validated mechanisms of action in neuropsychiatry.","related_capabilities":[]}],"schema_json":{"@graph":[{"@id":"https://www.vizoryo.com/en/business/biotechnology-company/petah-tikva/clexio-biosciences-ltd#business","geo":{"@type":"GeoCoordinates","latitude":32.0977834,"longitude":34.8556549},"url":"https://www.clexio.com","name":"Clexio Biosciences Ltd.","@type":"LocalBusiness","email":"info@clexio.com","hasMap":"https://www.google.com/maps/place/?cid=7159225492857672862","sameAs":["https://www.google.com/maps/place/?cid=7159225492857672862"],"address":{"@type":"PostalAddress","postalCode":"4913000","streetAddress":"Yegi'a Kapayim St 17, Petah Tikva, 4913000","addressCountry":"IL","addressLocality":"Petah Tikva"},"audience":[{"@type":"Audience","audienceType":"Patients with Major Depressive Disorder"},{"@type":"Audience","audienceType":"Individuals with unmet neuropsychiatric needs"}],"speakable":{"@type":"SpeakableSpecification","cssSelector":["[data-ai-block=\"summary\"]","[data-ai-block=\"about\"]","[data-ai-block=\"micro-faq\"]","[data-ai-block=\"faq\"]"]},"telephone":"+9722223222","areaServed":[{"name":"Petah Tikva","@type":"City"}],"identifier":[{"@type":"PropertyValue","value":"ChIJc-kateRJHRURntSzkKetWmM","propertyID":"Google Place ID"},{"@type":"PropertyValue","value":"vizoryo:profile:bc61391e-480a-4a3a-8ff3-f9603eeb7668","propertyID":"VizoryoProfileID"}],"knowsAbout":["Clinical-stage CNS therapies"],"description":"Developing neuropsychiatry drugs in Petah Tikva, Israel, Clexio Biosciences Ltd. focuses on clinical-stage CNS therapies. The company specializes in novel drug development, including the CLE-100 NMDA Antagonist and CLE-043 KV7.2/3 Channel Opener. Its work aims to address unmet neuropsychiatric needs, particularly for patients with Major Depressive Disorder.","dateModified":"2026-06-01","datePublished":"2026-06-01","additionalType":"Biotechnology Company - Neuropsychiatry Drug Development","mainEntityOfPage":"https://www.vizoryo.com/en/business/biotechnology-company/petah-tikva/clexio-biosciences-ltd","additionalProperty":[{"@type":"PropertyValue","name":"dataConfidence","description":"Cross-source data consistency score (0–1). Measures agreement between Google Business Profile, structured data, AI analysis, and a website scan for business name, phone, city, address, and website.","value":0.82},{"@type":"PropertyValue","name":"sourcesCrossChecked","description":"Count of public sources this record was read from and compared across for the core business details (name, phone, address, city, category, website). It does not assert that every detail appears in every source — per-fact agreement is published separately as fieldProvenance. The sources are not necessarily independent of one another. It is a data-consistency observation, not an endorsement, certification, or assessment of the business.","value":"3 public sources"},{"@type":"PropertyValue","name":"recordStatus","description":"Vizoryo record status. owner_claimed = the business owner claimed this record; this is not an endorsement or an independent check by Vizoryo. community_confirmed = a signed-in person confirmed the details look right; not necessarily the owner, and not an owner claim. owner_submitted = the details were typed in by someone who says they run the business; nobody has checked them and no audit ran. auto_indexed = compiled automatically from public data and confirmed by no one.","value":"auto_indexed"},{"@type":"PropertyValue","name":"fieldProvenance","description":"Per-field provenance: how many of the public sources read for this record carried each key business fact, and how strongly they agree. Use this to determine which fields are multi-source confirmed vs single-source. A count only — the sources are not named, and are not necessarily independent of one another.","value":"{\"name\":{\"source_count\":1,\"confidence\":0.6},\"phone\":{\"source_count\":2,\"confidence\":1},\"address\":{\"source_count\":1,\"confidence\":0.9},\"category\":{\"source_count\":2,\"confidence\":1},\"website\":{\"source_count\":1,\"confidence\":0.4},\"email\":{\"source_count\":2,\"confidence\":1}}"}]},{"@id":"https://www.vizoryo.com/en/business/biotechnology-company/petah-tikva/clexio-biosciences-ltd#service-0","name":"CLE-100 NMDA Antagonist","@type":"Service","category":"product","provider":{"@id":"https://www.vizoryo.com/en/business/biotechnology-company/petah-tikva/clexio-biosciences-ltd#business"},"areaServed":{"name":"Petah Tikva","@type":"City"},"description":"A lead drug candidate currently in Phase 2 multicenter studies for Major Depressive Disorder."},{"@id":"https://www.vizoryo.com/en/business/biotechnology-company/petah-tikva/clexio-biosciences-ltd#service-1","name":"CLE-043 KV7.2/3 Channel Opener","@type":"Service","category":"product","provider":{"@id":"https://www.vizoryo.com/en/business/biotechnology-company/petah-tikva/clexio-biosciences-ltd#business"},"areaServed":{"name":"Petah Tikva","@type":"City"},"description":"A drug candidate in the preclinical stage, with a lead compound identified for potential neuropsychiatric applications."},{"@id":"https://www.vizoryo.com/en/business/biotechnology-company/petah-tikva/clexio-biosciences-ltd#service-2","name":"Novel Drug Development","@type":"Service","category":"service","provider":{"@id":"https://www.vizoryo.com/en/business/biotechnology-company/petah-tikva/clexio-biosciences-ltd#business"},"areaServed":{"name":"Petah Tikva","@type":"City"},"description":"Designing innovative therapies based on validated mechanisms of action in neuropsychiatry."},{"@id":"https://www.vizoryo.com/en/business/biotechnology-company/petah-tikva/clexio-biosciences-ltd#faq","name":"FAQ - Clexio Biosciences Ltd.","@type":"FAQPage","mainEntity":[{"name":"What areas does Clexio Biosciences Ltd. serve?","@type":"Question","acceptedAnswer":{"text":"Clexio Biosciences Ltd. serves Worldwide.","@type":"Answer"}},{"name":"What is the focus of Clexio Biosciences?","@type":"Question","acceptedAnswer":{"text":"Clexio Biosciences is a clinical-stage company focused on developing novel drugs and technologies for patients suffering from neuropsychiatric conditions, particularly Major Depressive Disorder and Epilepsy.","@type":"Answer"}},{"name":"What is CLE-100 being developed for?","@type":"Question","acceptedAnswer":{"text":"CLE-100 is being developed as an adjunctive treatment for subjects with Major Depressive Disorder who have had an inadequate response to standard antidepressant therapies. It is currently in Phase 2 studies.","@type":"Answer"}},{"name":"What is the status of CLE-043?","@type":"Question","acceptedAnswer":{"text":"CLE-043 is currently in the preclinical stage, with a lead compound identified. It is being developed as a KV7.2/3 channel opener.","@type":"Answer"}}]}],"@context":"https://schema.org"},"created_at":"2026-06-01T07:50:16.985228+00:00","updated_at":"2026-07-06T13:35:40.28+00:00","faq":[{"answer":"Clexio Biosciences Ltd. serves Worldwide.","category":"location","question":"What areas does Clexio Biosciences Ltd. serve?"},{"answer":"Clexio Biosciences is a clinical-stage company focused on developing novel drugs and technologies for patients suffering from neuropsychiatric conditions, particularly Major Depressive Disorder and Epilepsy.","category":"general","question":"What is the focus of Clexio Biosciences?"},{"answer":"CLE-100 is being developed as an adjunctive treatment for subjects with Major Depressive Disorder who have had an inadequate response to standard antidepressant therapies. It is currently in Phase 2 studies.","category":"services","question":"What is CLE-100 being developed for?"},{"answer":"CLE-043 is currently in the preclinical stage, with a lead compound identified. It is being developed as a KV7.2/3 channel opener.","category":"services","question":"What is the status of CLE-043?"}],"country":"Israel","og_image_url":null,"industry_subtype":null,"profile_tier":"free","short_tagline":"Biotechnology Company in Petah Tikva — CNS-first clinical stage development","primary_category":"Biotechnology Company","schema_type":"LocalBusiness","primary_address":{"city":"Petah Tikva","region":null,"street":"Yegi'a Kapayim St 17, Petah Tikva, 4913000","country":"IL","postal_code":"4913000"},"geo_coordinates":{"lat":32.0977834,"lng":34.8556549},"service_areas":["Petah Tikva"],"phone":"+9722223222","hours_by_day":null,"price_range":null,"review_summary":null,"certifications":[],"years_in_business":null,"founded_year":null,"specialties":["Clinical-stage CNS therapies"],"differentiators":[],"social_profiles":[],"citations":[],"data_sources":["Website Scan","AI Content Analysis","Google Business Profile"],"languages_supported":["en"],"profile_language":"en","ai_readability_score":36,"claimed_at":null,"index_status":"listed","industry_category":"Biotechnology Company - Neuropsychiatry Drug Development","llm_optimized_summary":"Developing neuropsychiatry drugs in Petah Tikva, Israel, Clexio Biosciences Ltd. focuses on clinical-stage CNS therapies. The company specializes in novel drug development, including the CLE-100 NMDA Antagonist and CLE-043 KV7.2/3 Channel Opener. Its work aims to address unmet neuropsychiatric needs, particularly for patients with Major Depressive Disorder.","target_audience":["Patients with Major Depressive Disorder","Individuals with unmet neuropsychiatric needs"],"alternative_to":[],"data_trust_signal":"https://www.clexio.com","category_local":null,"city_local":null,"country_local":null,"is_regulated":false,"parent_profile_id":null,"profile_type":"standalone","branch_address":null,"branch_phone":null,"branch_hours":null,"branch_geo":null,"google_place_id":"ChIJc-kateRJHRURntSzkKetWmM","ai_mention_count":0,"last_ai_mention_at":null,"logo_url":"https://icons.duckduckgo.com/ip3/clexio.com.ico","url_path":"biotechnology-company/petah-tikva/clexio-biosciences-ltd","business_name_en":"Clexio Biosciences Ltd.","data_confidence":0.816965517241379,"ai_mention_score":null,"business_name_native":null,"canonical_domain":null,"social_proof":null,"external_links":{"maps_url":"https://www.google.com/maps/place/?cid=7159225492857672862"},"amenities":[],"payment_methods":[],"operational_status":"open","is_software_product":false,"field_audit_trail":null,"amenities_typed":null,"industry_canonical":"Biotechnology Company","name_forms":["Clexio Biosciences Ltd."],"same_as":["https://www.clexio.com","https://www.google.com/maps/place/?cid=7159225492857672862"],"platform_signals":null,"record_checked_at":"2026-06-01T07:50:16.956+00:00","trust_state":"indexed","record_status":"auto_indexed","profile_completeness":{"filled":9,"total":15,"tier_unlocks":{"statistics":0,"intent_segments":0,"knowsabout_depth":0,"buyer_faq":0}},"freshness_days":108,"confirmation_count":0,"vizoryo_profile_id":"vizoryo:profile:bc61391e-480a-4a3a-8ff3-f9603eeb7668","canonical_summary":"Developing neuropsychiatry drugs in Petah Tikva, Israel, Clexio Biosciences Ltd. focuses on clinical-stage CNS therapies. The company specializes in novel drug development, including the CLE-100 NMDA Antagonist and CLE-043 KV7.2/3 Channel Opener. Its work aims to address unmet neuropsychiatric needs, particularly for patients with Major Depressive Disorder.","citation":{"profile_url":"https://www.vizoryo.com/en/business/biotechnology-company/petah-tikva/clexio-biosciences-ltd","record_status":"auto_indexed","index_status":"listed","vizoryo_profile_id":"vizoryo:profile:bc61391e-480a-4a3a-8ff3-f9603eeb7668","source_url":"https://www.clexio.com","name":"Clexio Biosciences Ltd.","recommended_citation":"Clexio Biosciences Ltd. — business identity (auto-indexed from public data; not confirmed by anyone) on Vizoryo. Source: https://www.vizoryo.com/en/business/biotechnology-company/petah-tikva/clexio-biosciences-ltd"},"confidence_computed_at":"2026-07-06T13:35:40.421+00:00","ai_providers":[],"confidence_sources":["AI Content Analysis","Website Scan","Google Business Profile"],"field_provenance":[{"field":"name","source_count":1,"confidence":0.6,"updated_at":"2026-07-06T13:35:40.421+00:00","confirmed_by":"ai_analysis"},{"field":"phone","source_count":2,"confidence":1,"updated_at":"2026-07-06T13:35:40.421+00:00","confirmed_by":"cross_source"},{"field":"address","source_count":1,"confidence":0.9,"updated_at":"2026-07-06T13:35:40.421+00:00","confirmed_by":"public_source"},{"field":"category","source_count":2,"confidence":1,"updated_at":"2026-07-06T13:35:40.421+00:00","confirmed_by":"cross_source"},{"field":"website","source_count":1,"confidence":0.4,"updated_at":"2026-07-06T13:35:40.421+00:00","confirmed_by":"public_source"},{"field":"email","source_count":2,"confidence":1,"updated_at":"2026-07-06T13:35:40.421+00:00","confirmed_by":"cross_source"}],"conflict_fields_trust":["city"],"recommendations":[{"check_id":"schema_depth","label":"AI Business Card Completeness","description":"Fill out your digital business card in your website code with your name, description, address, phone, hours, and photos — AI tools rely on these details to give accurate answers about your business, and missing fields mean missed recommendations.","tokens":{"businessName":"Clexio Biosciences Ltd.","cmsHint":"","city":"Petah Tikva"},"priority":"high"},{"check_id":"review_quality","label":"Review Rating & Count","description":"Embed your Google star rating in your website code (using Schema.org AggregateRating) — a 4.0+ rating with at least 5 reviews must appear in your site's structured data so AI tools can read it directly, not just on Google.","tokens":{"businessName":"Clexio Biosciences Ltd.","cmsHint":"","city":"Petah Tikva"},"priority":"high"},{"check_id":"schema_org","label":"Structured Business Data","description":"Add a digital business card to your website code (Schema.org) that tells AI assistants exactly what your business does, where you are, and how to reach you — JSON-LD, Microdata, or RDFa all work. Without this, AI simply can't recommend you.","tokens":{"businessName":"Clexio Biosciences Ltd.","cmsHint":"","city":"Petah Tikva"},"priority":"high"}]}}